2403#012

RULE

Department of Health
Board of Pharmacy

Prescription Monitoring Program
(LAC 46:LIII.2901 and 2914)

In accordance with the provisions of the Administrative Procedure Act (R.S. 49:950 et seq.) and the Pharmacy Practice Act (R.S. 37:1161 et seq.), the Board of Pharmacy amended §2901 and §2914 of its rules relative to the Prescription Monitoring Program (PMP). The Rule change in §2901 clarifies intent in regards to butalbital containing products and removes naloxone as a drug of concern. The Rule change in §2914 addresses record retention of PMP information. This Rule is hereby adopted on the day of promulgation.

Title 46
PROFESSIONAL AND OCCUPATIONAL STANDARDS
Part LIII. Pharmacists
Chapter 29. Prescription Monitoring Program

§2901. Definitions

A. As used in this Chapter, the following terms shall have the meaning ascribed to them unless the context clearly indicates otherwise.

* * *

Drugs of Concern—drugs other than controlled substances as defined by rule whose use requires tracking for public health purposes or which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation]:

a. butalbital.

b. promethazine when present in oral liquid formulation.

c. gabapentin.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR 36:755 (April 2010), effective September 1, 2010, LR 39:314 (February 2013), LR 40:1095, 1096 (June 2014), LR 41:684 (April 2015), amended by the Department of Health, Board of Pharmacy, LR 45:42 (January 2019), LR 47:84 (January 2021), repromulgated LR 47:248 (February 2021), amended LR 50:390 (March 2024).

§2914. Record Retention of Prescription Monitoring Information

A. The board shall retain a minimum of five years of prescription monitoring information for review by persons authorized to access such information.

B. The board shall archive all prescription monitoring information not available for direct or indirect access up to 10 years.

C. The board may remove and destroy prescription monitoring information in excess of 10 years.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1006(G).

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 47:85 (January 2021), repromulgated LR 47:248 (February 2021), amended LR 50:390 (March 2024).

M. Joseph Fontenot Jr.
Executive Director

2403#013